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Abstract
Background Elevated red blood cell distribution width (RDW) is a valid predictor of outcome in acute heart failure (AHF). It is
unknown whether elevated RDW remains predictive in AHF patients with either preserved left ventricular ejection fraction
(LVEF) ≥50% or reduced LVEF (<50%).
Methods and results Prospective local registry including 402 consecutive hospitalized AHF patients without acute coronary
syndrome or need of intensive care. The primary outcome was all-cause mortality (ACM) at 1 year after admission.
Demographic and clinical data derive from admission, echocardiographic examinations (n = 269; 67%) from hospitalization.
The Cox proportional hazard model including all patients (P< 0.001) was adjusted for age, gender, and RDW quartiles.
Independent predictors of 1-year ACM were cardiogenic shock (HR 2.86; CI: 1.3–6.4), male sex (HR 1.9; CI: 1.2–2.9), high
RDW quartile (HR 1.66; CI: 1.02–2.8), chronic HF (HR 1.61; CI: 1.05–2.5), valvular heart disease (HR 1.61; CI: 1.09–2.4),
increased diastolic blood pressure (HR 1.02 per mmHg; CI: 1.01–1.03), increasing age (HR 1.04 by year; CI: 1.02–1.07),
platelet count (HR 1.002 per G/l; CI: 1.0–1.004), systolic blood pressure (HR 0.99 per mmHg; CI: 0.98–0.99), and weight
(HR 0.98 per kg; CI: 0.97–0.99). A total of 114 patients (28.4%) died within the ﬁrst year; ACM of all patients increased
with quartiles of rising RDW (χ2 18; P< 0.001). ACM was not different between RDW quartiles of patients with reduced
LVEF (n = 153; χ2 6.6; P = 0.084). In AHF with LVEF ≥50% the probability of ACM increased with rising RDW (n = 116; χ2 9.9;
P = 0.0195).
Conclusions High RDW is associated with increased ACM in AHF patients with preserved but not with reduced LVEF in this
study population.
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Background
Acute heart failure (AHF) is associated with an adverse
prognosis with an all cause mortality (ACM) of 10–20% at
2–3months and 17–37% at 1 year.1–5 Single biomarkers on
top of clinical assessment are useful for risk stratiﬁcation in
patients with chronic heart failure (HF).6,7 However in AHF,
the incremental predictive value of a single biomarker is small
when added to a clinical score. Results from the
Multinational Observational Cohort on Acute Heart Failure
(MOCA) study suggest improved risk prediction when
miscellaneous biomarkers are assessed simultaneously.5 This
concept accounts for the absence of one single relevant
pathomechanism in AHF while accepting that interpretation
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of test results is more difﬁcult. Red cell distribution width
(RDW) is a readily available biomarker increasing with
cytokine activation, impaired iron mobilization, and
decreasing haemoglobin level.8–10 RDW, thus, integrates
various pathophysiological mechanisms associated with HF
progression, which can explain why elevated RDW is a robust
marker of risk for mortality in acute and chronic HF.11–13 This
prospective registry of consecutive patients hospitalized for
AHF investigates whether elevated RDW remains predictive
in AHF patients when patients are grouped by LVEF ≥50%
or LVEF <50%.
Methods
This is a prospective registry of consecutive patients (n = 408)
hospitalized for AHF at a tertiary centre. Patients presenting
with AHF at the Emergency Wards were included when
hospitalized for heart failure at our institution and after
signing the consentment. Patients with acute coronary
syndrome, or cardiogenic shock in need of intensive care
were not included. Outcome parameter of this registry was
1-year all cause mortality (ACM). Patients without outcome
(n = 6) were excluded from ﬁnal analysis. The local ethical
committee approved the study protocol.
Demographic, clinical, and laboratory data were obtained
at admission. Echocardiographic data derive from standard
transthoracic studies signed by a board-certiﬁed cardiologist
at our institution; all exams were performed during index
hospitalization. Physicians’ diagnosis of co-morbidity followed
the respective guidelines.14–16 RDW was measured using the
Advia 120 Hematology Analyzer (Siemens Healthcare
Diagnostics). RDW was reported as coefﬁcient of variation
(in percent) of erythrocyte cell volume.
Statistical analysis
Continuous variables are presented as mean (± SD) or median
(± interquartile range; IQR). Categorical variables are
presented as numbers and percentages. Analysis of variance
compared continuous variables, and χ2-statistic compared
categorical variables.
RDW quartiles were deﬁned in accordance with the
literature13,17,18 with the lowest quartile serving as the
reference group. The distribution of RDW was skewed;
therefore, logarithmically transformed values of RDW (ln
RDW) were used as dependent variable for multiple linear
regressions as reported elsewhere.13 Age, gender, and RDW
quartiles were forced into the model predicting ACM;
independent explanatory variables were identiﬁed by
backward elimination of variables associated with RDW at a
probability (P) of <0.1 in univariate analysis.
Stepwise Cox proportional hazards models calculated the
hazard ratio (HR) selecting covariables on the basis of
backward stepwise analysis with removal set at P< 0.1.
Survival curves were calculated using the Kaplan–Meier
method; comparison of survival curves used the log-rank test.
All tests were two-sided and used a signiﬁcance level of
P< 0.05. Analyses were performed using the R statistical
software (version R 3.1.0) (R development core team).
Results
Patients with high RDW were older, had a higher incidence of
previous HF-related hospitalizations, and chronic HF was
more prevalent by trend (P = 0.0612). Patients in the high
RDW quartile had lower LVEF, lower systolic and diastolic
blood pressure, and lower haemoglobin; creatinine, C-
reactive protein, and NT-proBNP levels were higher. Patients
with high RDW received more often loop diuretics and oral
anticoagulation (Table 1).
Table 2 depicts clinical and laboratory parameters
independently associated with RDW. The ﬁnal model
explained 37% of the variability in RDW. RDW was
independently related with in-hospital mortality (P = 0.008).
Correlation was poor between RDW and LVEF (P = 0.21), eGFR
(P = 0.12), or length of stay (P = 0.10). RDW levels and
haemoglobin levels correlated with strength of 0.0021
± 0.0002 (P = 0.021).
Table 3 shows the results of a multivariable Cox model
(maximal logistical likelihood 614.37; LR test statistic:
79.74; P = 1.2 × 1011). The following variables were
associated with increased HR (listed in increasing order):
platelets, age, diastolic blood pressure, valvular pathology,
chronic HF, elevated RDW, male sex, and cardiogenic shock.
Variables with a decreased HR are listed in decreasing order:
lower RDW, weight, and systolic blood pressure.
Haemoglobin level was not retained in the proportional
hazards model predicting 1-year ACM.
During follow-up 114 patients (28.4%) died. The Kaplan–
Meier analysis including all patients showed a graded
increased probability of mortality with increasing quartile of
RDW (Figure 1(A); χ2 18; P = 0.0004). In patients with reduced
LVEF, mortality was not signiﬁcantly different between RDW
quartiles (Figure 1(B); χ2 6.6; P = 0.084). Study patients with
preserved LVEF showed a graded increased probability of
mortality with rising RDW quartile (Figure 1(C); χ2 9.9;
P = 0.0195).
Table 4 compares characteristics of AHF patients with
preserved and reduced LVEF. AHF patients with preserved
LVEF were older, the number of previous hospitalizations for
HF was lower, and the prevalence of female gender and
diagnosis of de novo HF was higher. AHF patients with
preserved LVEF more often presented with hypertensive
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crisis whereas prevalence of ischemic aetiology and diabetes
was lower. The prevalence of valvular pathology was not
signiﬁcantly different between HF patients with preserved
and reduced systolic ejection fraction. In AHF patients with
preserved LVEF systolic blood pressure was higher while
heart rate and NT-proBNP levels were lower.
Overall 19.9% of all patients presented with high RDW,
65% of these patients had a transthoracic echocardiography
during hospitalization; 63.4% of these presented a LVEF
<50%. Patients with LVEF ≥50% and high RDW were older
(80 vs. 75 y; P = 0.013), heart rate was lower (80 vs. 90 bpm
P = 0.04), and history of HF was less frequent (47 vs. 79%,
P = 0.04). The burden of comorbidities (i.e. diabetes, arterial
hypertension, chronic obstructive bronchopulmonary
disease, BMI, renal dysfunction by eGFR) was not signiﬁcantly
different between patients with high RDW and LVEF of <50%
or ≥50%.
Table 1 Characteristics of RDW quartiles
Quartiles RDW [12.2,14.2] [14.3,15.2] [15.3,16.6] [16.7,32.1] P-value
Number (n) 133 91 98 80
Demographics
Age (y) 76 (64–83) 80 (74–85.5) 78 (71–83) 79 (74–83) 0.0093
Male gender (%) 83 (62.4) 47 (51.6) 58 (59.2) 45 (56.2) 0.4363
Prev. HHF (%) 23 (17.3) 19 (20.9) 23 (23.5) 31 (38.8) 0.0041
CHF (%) 72 (54.1) 57 (62.6) 67 (68.4) 56 (70) 0.0612
In hospital mort (%) 6 (4.5) 5 (5.5) 5 (5.1) 9 (11.2) 0.2055
LoS (days) 9 (4–15) 11 (4–15) 9 (4–16) 11 (5–15) 0.6543
Classiﬁcation
CS (%) 3.8 4.4 4.1 5 0.9768
PE (%) 28 25.3 21.4 27.5 0.6535
RHF (%) 4.5 7.7 17.3 16.2 0.0042
HTN crisis (%) 14.3 13.2 7.1 5 0.0873
Decomp HF (%) 48.8 49.4 50 46.3 0.9637
Characteristics
LVEF (%) 42 (30–60) 50 (40–60) 40 (25–60) 40 (25–60) 0.0259
HR (bpm) 91 (77–105) 87.5 (72–105) 94 (79–107) 90(75–106) 0.6373
SR (%) 73 (54.9%) 49 (53.8%) 50 (51%) 38 (47.5%) 0.7207
SBP (mmHg) 151 (130–168) 144 (126–171) 142(128–166) 129 (114–151) 0.0001
DBP (mmHg) 86 (76–96) 84 (68–97) 82.5 (76–93) 77 (64–88) 0.0008
BMI 26.9 (24–31) 26.1 (23–32) 26 (24–30) 25 (23–29) 0.7347
Comorbidities
Diabetes (%) 36.8 35.2 37.8 51.2 0.1315
Hypertension (%) 82.7 84.6 87.8 83.8 0.7474
COBP (%) 18 20.9 7.1 11.2 0.0242
Biological test
Crea (mmol/l) 101 (80–128) 102 (82–137) 106 (88–152) 112 (94–157) 0.0170
CRP (mg/l) 10 (4–61) 16 (9–53) 14.5 (6–30) 20.5 (10–51) 0.0816
NT-proBNPx103 (pg/ml) 3.8 (1.9–6.8) 3.0 (1.3–4.4) 6.8 (3.3–10.1) 7.8 (3.5–16.2) 0.0021
Haemoglobin (G/l) 130 (116–146) 127 (114–136) 121 (107–141) 114 (99–125) 0.0000
Platelets (G/l) 219 (173–280) 225 (190–263) 233 (190–300) 225 (169–288) 0.6993
Medication
Betablocker (%) 36.1 38.5 39.8 43.8 0.7367
ACE-I (%) 37.6 35.2 42.9 48.8 0.2588
ARB (%) 26.3 27.5 31.6 17.5 0.1941
MR-blocker (%) 9.8 12.1 21.4 20 0.0438
Loop diuretic (%) 45.9 48.4 65.3 70 0.0006
Digoxin (%) 11.3 13.2 15.3 18.8 0.4809
ASA (%) 51.1 53.8 52 57.5 0.8375
OAC (%) 24.8 36.3 43.9 53.8 0.0002
Clopidogrel (%) 18.8 23.1 23.5 17.5 0.6319
Prev. HHF, previous hospitalization for heart failure; in hosp mortality, in hospital mortality; LoS, length of stay; CS, cardiogenic shock; PE,
pulmonary edema; RHF, right heart failure; HTN, hypertension; decomp HF: decompensated heart failure; LVEF, left ventricular ejection
fraction; HR, heart rate; SR, sinus rhythm; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; COPD, chronic
obstructive pulmonary disease.
Table 2 Strength of the correlation between RDW (ln RDW) and
different variables
Estimate (SD) P-value
Age 0.0016 (0.0005) 0.002
SBP -0.0005 (0.0002) 0.021
Haemoglobin –0.0021 (0.0002) <0.0001
Leucocytes 0.0050 (0.0009) <0.0001
Oral anticoagulation –0.0422 (0.0210) 0.0461
Prothrombin time –0.0015 (0.0003) <0.0001
Prev HHF 0.02448 (0.0131) 0.0637
Right heart failure 0.0607 (0.0174) 0.000556
Diabetes mellitus 0.0297 (0.0113) 0.0088
See legend Table 1.
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Discussion
The results of the present study add to the available data
regarding the predictive relevance of elevated RDW in acute
HF. First, the results conﬁrm the relevance of high RDW for
prediction of mortality in AHF.11–13 Second, the present study
population shows that high RDW is associated with increased
mortality in AHF patients with LVEF ≥50% while there is no
interaction between high RDW and mortality in AHF patients
with LVEF< 50%.
The small size of the present study population raises the
concern whether the sample is representative. However,
demographic, clinical, and biological characteristics of the
present study collectively correspond with respective
characteristics reported from larger studies in AHF.19,20 In
addition, the present study replicates associations between
Figure 1 (A) RDW quartiles and 1-year survival of all AHF patients. (B) RDW quartiles and 1-year survival in AHF patients with LVEF <50%. (C) RDW
quartiles and 1-year survival in AHF patients with LVEF ≥50%.
A B
C
Table 3 Adjusted proportional hazards model for all cause 1-year
mortality
Covariate Mean/(%) HR (97.5% CI) P-value
Age (y) 75.2 1.044 (1.02–1.07) <0.0001
Gender (male) 58% 1.904 (1.24–2.93) 0.030
RDW quartile
(14.3–15.2) 0.24 0.761 (0.43–1.34) 0.341
(15.2–16.6) 0.25 0.877 (0.51–1.51) 0.638
(16.6–32.1) 0.17 1.686 (1.02–2.79) 0.041
Weight (kg) 79 0.978 (0.97–0.99) 0.001
Syst. BP (mmHg) 147 0.985 (0.98–0.99) 0.002
Diast. BP (mmHg) 85 1.020 (1.01–1.03) 0.011
Card. shock 3.6% 2.864 (1.29–6.35) 0.010
Platelets (G/l) 235 1.002 (1.0–1.004) 0.018
Chronic HF 60.9% 1.611 (1.05–2.48) 0.030
β-blocker 42.5% 0.735 (0.50–1.09) 0.128
Valvular HD 46.4% 1.606 (1.09–2.38) 0.018
Female gender and lowest RDW group were used as reference;
valvular HD, valvular heart disease.
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RDW and outcome as described elsewhere, in particular, the
negative correlation of RDW with haemoglobin levels as
reported in the Candesartan in Heart Failure: Assessment of
the Reduction in Mortality and Morbidity (CHARM),8 and in
the STAMINA-HFP (Study of Anemia in HF Population) or
the UNITE-HF (United Investigators to Evaluate Heart Failure)
registry.9 In addition, this study replicates the relation of high
RDW with increased mortality already described in other AHF
study populations.11–13 Finally, high RDW was retained in the
model for prediction of ACM similar to other studies in acute
or chronic HF.8,13,17
In the general population, RDW increases with conditions
of ineffective red cell production (such as iron deﬁciency,
folate or B12 deﬁciency, and hemglobinopathy), increased
red cell destruction, or after blood transfusion. Anaemia is a
strong predictor of mortality in heart failure suggesting that
RDW is a strong predictor for mortality and morbidity8,10,12
because of the high prevalence of anaemia.8 In fact, some
heart failure studies link elevated RDW with inﬂammation,
malnutrition, and renal dysfunction that may all impact on
erythropoiesis.18,21 However, results from the CHARM North
America study cohort (n = 2697) indicate a prognostic role of
RDW that is independent from haemoglobin level based on
the observation that both parameters were retained in the
ﬁnal model for prediction of ACM but without reciprocal
interaction.8 This observation was replicated in the Duke
Databank cohort providing supportive evidence.8 Additional
evidence for a distinct role of RDW derives from the
European Prospective Investigation into Cancer and Nutrition
(EPIC) Norfolk study and the Malmö Cancer and Diet study
which show an association of RDW with incident heart failure
while RDW was in this middle-aged healthy population
without relation to iron metabolism or inﬂammation.22,23
High RDW is associated with increased interleukin-6 levels
(IL-6) as shown in the STAMINA-HFP and the UNITE-HF
registries.9 In patients with mild or moderate HF with
reduced LVEF, increased IL-6 levels are associated with
increased risk of disease progression.24 Furthermore, IL-6
Table 4 Demographics and characteristics of AHF patients with reduced and preserved ejection fraction
All LVEF ≥ 50% LVEF< 50% P-value
Number (n) 402 117 154
Demographics
Age (y) 78 (70–84) 79 (74–84) 73 (64–81) <0.0001
Gender (male, %) 234 (57.4) 48 (41) 110 (71.4) <0.0001
Previous HHF (%) 96 (23.5) 22 (18.8) 49 (31.8) 0.023
Hx of CHF (%) 252 (61.8) 52 (44.4) 113 (73.4) <0.0001
LVEF 40 (30–60) 60 (55–65) 30 (25–40) <0.0001
ICD (%) 19 (4.7) 0 (0) 15 (9.7) 0.001
Pacemaker (%) 49 (12) 10 (8.5) 24 (15.6) 0.12
Phenotype of AHF
Cardiogenic shock 17 (4.2) 2 (1.7) 11 (7.1) 0.07
Pulmonary oedema 104 (25.5) 30 (25.6) 45 (29.2) 0.61
RH decompensation 44 (10.8) 10 (8.5) 20 (13) 0.34
Hypertensive crisis 42 (10.3) 21 (17.9) 3 (1.9) <0.0001
Global decompensation 193 (49.2) 54 (46.3) 75 (48.8) 0.12
Cardiac pathology
CAD (%) 232 (56.9) 53 (45.3) 107 (69.5) <0.0001
LV dilatation (%) 6 (5.1) 81 (52.6) <0.0001
Mild MR (%) 88 (75.2) 146 (94.8) 0.16
Moderate MR (%) 9 (7.7) 8 (5.2)
Mild AR (%) 51 (43.6) 81 (52.3) 0.37
Moderate AR (%) 2 (1.8) 2 (1.3)
Comorbidity
Diabetes mellitus (%) 159 (39) 35 (29.9) 73 (47.4) 0.005
Hypertension (%) 341 (83.6) 100 (85.5) 125 (81.2) 0.44
COBP (%) 159 (14.5) 3 (11.1) 23 (14.9) 0.46
BMI 26 (24–31) 26 (24–29) 26 (24–31) 0.56
Biological parameters
SBP (mmHg) 142 (124–164) 150 (132–170) 133 (120–151) <0.0001
DBP (mmHg) 84 (72–94) 81 (74–93) 84 (72–92) 0.76
Heart rate (bpm) 90 (75–105) 83 (70–100) 97 (84–117) <0.0001
Sinus rhythm (%) 211 (51.7) 67 (57) 82 (53) 0.59
Creatinine (mmol/l) 105 (84–141) 97 (81–134) 109 (86–151) 0.054
NT-proBNPx103 (pg/ml) 4.5 (2.1–9.5) 3.3 (1.7–7.8) 6.8 (3.9–13.4) 0.002
CRP (mg/l) 15(6–47) 14.5 (6–54) 13 (6–44) 0.54
NIPV (%) 138 (33.8) 39 (33.3) 60 (39%) 0.41
In hosp mortality n (%) 26 (6.4) 5 (4.3) 10 (6.5) 0.60
LoS (days) 10 (4–15) 10 (6–17) 11 (7–16) 0.62
See legend Table 1, NIPV, non-invasive pulmonary ventilation, for others see Table 1. Parenthesis indicates IQR if not indicated otherwise.
P-values refer to comparison of HF patients with reduced or preserved LVEF.
CAD, coronary artery disease; MR, mitral regurgitation; AR, aortic regurgitation.
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are likely to be relevant in HF with preserved HF as suggested
in a study by Collier et al. which showed an increase of IL-6
levels in patients with LVEF ≥50% and heart failure symptoms
while IL-6 was low in patients without HF symptoms.25,26
Complementary evidence of a pathophysiological role of IL-
6 in HF derives from the Health, Aging, and Body Composition
(ABC) study that showed a correlation between increased IL-6
levels and incident HF with preserved LVEF.27 Because blood
samples were not retained from the present study
population, we cannot correlate RDW with IL-6 levels;
however, increased CRP levels in patients with high RDW
suggest increased IL-6 levels because IL-6 levels correlate
with CRP levels patients with AHF and chronic HF.24,28
In the present study, high RDWwas associated with increased
mortality in patients with LVEF≥ 50% while mortality was not
different between RDW groups of patients with reduced LVEF.
Several characteristics of the two subgroups may explain this
ﬁnding: ﬁrst, evidence-based pharmacological treatment6 was
increased in the majority of patients with reduced LVEF <50%
during hospitalization (inhibitors of the renin–angiotensin
system: 70% to 92%; β-blocker treatment: 35 to 58%;
antagonists of the mineralocorticoid receptor: 21 to 38%). It is
well known that increase of pharmacological HF treatment
improves 1-year survival;6,13 therefore, mortality difference
between the RDW quartiles in the present study may have
decreased because of improved drug therapy; second, more
patients with preserved LVEF and low RDW had developed
AHF because of hypertensive crisis. Hypertensive crisis is
associated with a low mortality29 suggesting accentuation of
the mortality difference between low and high RDW quartiles;
third, recent results from the Swedish Heart failure registry
suggest that β-blocker treatment reduces ACM in HF patients
with preserved LVEF.30 Only 42% of the study patients with
preserved LVEF≥ 50% were on β-blocker treatment suggesting
an increased hazard for mortality in patients without β-blocker
in accordance with the proportional hazards model of this study.
In fact, β-blocker treatment decreased from 52% to 41% in
patients with preserved LVEF and high RDW.
Study limitations
The single-centre study design, the sample size, and the
outcome parameter of 1-year all-cause mortality without
consideration of cardiovascular mortality or rehospitalization
rate represent limitations of the study. Furthermore,
echocardiograms were not obtained in all patients, which
might have introduced a selection bias. However,
characteristics of patients with or without echocardiogram
were not signiﬁcantly different.
Conclusions
We have shown for the ﬁrst time the prognostic relevance of
RDW in AHF with preserved ejection suggesting that RDW
may help to stratify risk already at admission. In a next step,
this observation should be conﬁrmed in a larger AHF
population with echocardiographic exams obtained during
index hospitalization. In addition, the results of this study
merit further work-up of the interaction of RDW and IL-6 in
AHF with preserved ejection fraction, and thus, increase our
understanding of clinically relevant pathomechanisms in
these patients.
Acknowledgement





CARDIOMET, an initiative of the CHUV to improve quality of
care in cardiovascular and metabolic disease; Swiss National
Science Foundation (320030_147121/1), SWISSHEART
Foundation, to R.H.
References
1. Curtis LH, Greiner MA, Hammill BG,
Kramer JM, Whellan DJ, Schulman KA,
Hernandez AF. Early and long-term
outcomes of heart failure in elderly
persons. Arch Intern Med 2008; 168:
2481–2488.
2. O’Connor CM, Stough WG, Gallup DS,
Hasselblad V, Gheorghiade M.
Demographics, clinical characteristics,
and outcomes of patients hospitalized
for decompensated heart failure:
observations from the IMPACT-HF
registry. J Card Fail 2005; 11: 200–205.
3. Gheorghiade M, Abraham WT, Albert
NM, Greenberg BH, O’Connor CM, She
L, Gattis Stough W, Yancy CW, Young
JB, Fonarow GC, for the OPTIMIZE-HF
Investigators and Coordinators et al.
Systolic blood pressure at admission,
clinical characteristics, and outcomes in
patients hospitalized with acute heart
failure. JAMA 2006; 296: 2217–2226.
4. Maggioni AP, Dahlstrom U, Filippatos G,
Chioncel O, Crespo Leiro M, Drozdz J,
Red cell distribution width and acute heart failure 203
ESC Heart Failure 2016; 3: 198–204
DOI: 10.1002/ehf2.12091
Fruhwald F, Gullestad L, Logeart D,
Fabbri G, Urso R, Metra M, Parissis J,
Persson H, Ponikowski P, Rauchhaus M,
Voors AA, Wendelboe Nielsen O, Zannad
F, Tavazzi L, on behalf of the Heart
Failure Association and the European
Society of Cardiology. EURObservational
Research Program: regional differences
and 1-year follow-up results of the Heart
Failure Pilot Survey (ESC-HF Pilot). Eur J
Heart Fail 2013; 15: 808–817.
5. Lassus J, Gayat E, Mueller C, Peacock
WF, Spinar J, Harjola VP, van
Kimmenade R, Pathak A, Mueller T, di
Somma S, Metra M, Pascual-Figal D,
Laribi S, Logeart D, Nouira S, Sato N,
Potocki M, Parenica J, Collet C, Cohen-
Solal A, Jauzzi JL, Mebazaa A, for the
GREAT-network. Incremental value of
biomarkers to clinical variables for mortality
prediction in acutely decompensated heart
failure: The Multinational Observational
Cohort on Acute Heart Failure (MOCA)
study. Int J Cardiol 2013; 168: 2186–2194.
6. McMurray JJ, Adomopoulos S, Anker
SD, Aurricchio A, Böhm M, Dickstein K,
Falk V, Filippatos G, Fonseca C, Gomez-
Sanchez MA, Jaarsma T, Kober L, Lip
GYH, Maggioni AP, Parkhomenko A,
Pieske BM, Popescu BA, Ronnevik PK,
Rutten FH, Schwitter J, Seferovic P,
Stepinska J, Trindade PT, Voors AA,
Zannad F, Zeiher A. ESC guidelines for
diagnosis and treatment of acute and
chronic heart failure. Eur Heart J 2012;
33: 1787–1847.
7. Hartmann F, Packer M, Coats AJS,
Fowler MB, Krum H, Mohacsi P, Rouleau
JL, Tendera M, Castaigne A, Anker SD,
Amann-Zalan I, Hoersch S, Katus HA.
Prognostic impact of plasma N-terminal
pro–brain natriuretic peptide in severe
chronic congestive heart failure: a
substudy of the carvedilol prospective
randomized cumulative survival
(COPERNICUS) trial. Circulation 2004;
110: 1780–1786.
8. Felker GM, Allen LA, Pocock SJ, Shaw
LK, McMurray JJ, Pfeffer MA, Swedberg
K, Wang D, Yusuf S, Michelson EL,
Granger CB, for the CHARM
Investigators. Red cell distribution width
as a novel prognostic marker in heart
failure. Data from the CHARM program
and the Duke databank. J Am Coll
Cardiol 2007; 50: 40–47.
9. Allen LA, Felker GM, Mehra MR, Chiong
JR, Dunlap SH, Ghali JK, Lenihan DJ,
Oren RM, Wagoner LE, Schwartz TA,
Adams KF. Validation and potential
mechanisms of red cell distribution
width as a prognostic marker in heart
failure. J Card Fail 2010; 16: 230–238.
10. Jenei ZM, Förhécz Z, Gombos T,
Pozsonyi Z, Janoskuit L, Prohaszka Z.
Red cell distribution width as predictive
marker in CHF: testing model
performance by reclassiﬁcation methods.
Int J Cardiol 2014; 174: 783–785.
11. Pascual-Figal DA, Bonaque JC, Redondo
B, Manzano-Fernandez S, Fernandez A,
Garrido IP, Pastor-Perez F, Lax A, Valdes
M, Januzzi JL. Red blood cell
distribution width predicts long-term
outcome regardless of anemia status in
acute heart failure patients. Eur J Heart
Fail 2009; 11: 840–846.
12. van Kimmenade RR, Mohammed AA,
Uthamalingam S, van der Meer P, Felker
GM, Januzzi JL. Red blood cell
distribution width and 1-year mortality
in acute heart failure. Eur J Heart Fail
2010; 12: 129–136.
13. Makhoul BF, Khourieh A, Kaplan M,
Badouth F, Aronson D, Azzam ZS.
Relation between changes in red cell
distribution width and clinical outcomes
in acute decompensated heart failure.
Int J Cardiol 2013; 167: 1412–1416.
14. Russi EW, Karrer W, Brutsche M, Eich C,
Fitting JW, Frey M, Geiser T, Kuhn M,
Nicod L, Quadri F, Rochat T, Steuer-Stey
C, Stolz D; Swiss Respiratory Society.
Diagnosis and management of chronic
obstructive pulmonary disease. Respiration
2013; 85: 160–174.
15. ESC task force for the management of
arterial hypertension. 2013 practice
guidelines for management of arterial
hypertension of the European Society
of Hypertension (ESH) and the
European Society of Cardiology (ESC):
ESH/ESC task force for the management
of arterial hypertension. J Hypertens
2013; 31: 1925–1938.
16. World Health Organization. (WHO)
consultation: Deﬁnition and diagnosis of
diabetes mellitus. Geneva: World Health
Organisation; 1999, Rapport 99.2. http:
//whqlibdoc.who.int/hq/1999/who_
ncdx_ncs_99.2pdf.
17. Zalawadiya SK, Zmily H, Farah J,
Daiffallah S, Amaima A, Ghali JK. Red
cell distribution width and mortality in
predominantly African–American
population with decompensated heart
failure. J Card Fail 2011; 17: 292–298.
18. Förhecz Z, Gombos T, Borgulya G,
Pozsonyi Z, Prohaszka Z, Janoskuti L.
Red cell distribution width in heart
failure: prediction of clinical events and
relationship with markers of ineffective
erythropoiesis, inﬂammation, renal
function, and nutritional state. Am Heart
J 2009; 158: 659–666.
19. Fonarow GC, Gattis Stough W, Abraham
WT, Albert NM, Gheorghiade M,
Greenberg BH, MD, O’Connor C, Sun
JL, Yancy CW, Young JB, for the
OPTIMIZE-HF Investigators and
Hospitals. Characteristics, treatments,
and outcomes of patients with preserved
systolic function hospitalized for heart
failure. A report from the OPTIMIZE-
HF registry. J Am Coll Cardiol 2007; 50:
768–777.
20. Ambrosy AP, Fonarow GC, Butler J,
Chioncel O, Greene SJ, Vaduganathan
M, Nodari S, Lam CSP, Sato N, Shah
AM, Gheorghiade M. The global health
and economic burden of hospitalizations
for heart failure. J Am Coll Cardiol 2014;
63: 1123–1133.
21. Roland RJ, van Kimmenade RR,
Mohammed AA, Uthamalingam S, van
der Meer P, Felker GM, Januzzi JL. Red
blood cell distribution width and 1-year
mortality in acute heart failure. Eur J
Heart Fail 2010; 12: 129–136.
22. Borné Y, Smith JG, Melander O,
Hedblad B, Engström G. Red cell
distribution width and risk for ﬁrst
hospitalization due to heart failure: a
population-based cohort study. Eur J
Heart Fail 2011; 13: 1355–1361.
23. Emans ME, Gaillard C, Pﬁster R, Tanck
MW, Matthijs Boekholdt S, Warham NJ,
Khaw K-T. Red cell distribution width is
associated with physical inactivity and
heart failure, independent of established
risk factors, inﬂammation or iron
metabolism; the EPIC-Norfolk study. Int
J Cardiol 2013; 168: 3550–3555.
24. PaulusWJ, Tschöpe C. A novel paradigm for
heart failure with preserved ejection action.
J Am Coll Cardiol 2013; 61: 263–271.
25. Kalogeropoulos A, Georgiopoulou V,
Psaty BM, Rodondi N, Smith AL,
Harrison DG, Yongmei L, Hoffmann U,
Bauer DC, Newmann AB, Kritchevsky
SB, Harris TB, Butler J, for the Health
ABC Investigators. Inﬂammatory
markers and incident heart failure risk
in older adults: the Health ABC (Health,
Aging, and Body Composition) study. J
Am Coll Cardiol 2010; 55: 2129–2137.
26. Collier P, Watson CJ, Voon V, Phelan D,
Jan A, Mak G, Martos R, Baugh JA,
Ledwidge MT, McDonald K. Can
emerging biomarkers of myocardial
remodelling identify asymptomatic
hypertensive patients at risk for diastolic
dysfunction and diastolic heart failure?
Eur J Heart Fail 2011; 13: 1087–1095.
27. Tanner H, Mohacsi P, Fuller-Bicer GA,
Rieben R, Meier B, Hess OM, Hullin R.
Cytokine activation and disease
progression in patients with stable
moderate chronic heart failure. J Heart
Lung Transplant 2007; 26: 622–629.
28. Milo-Cotter O, Cotter-Davison B,
Lombardi C, Sun H, Bettari L, Bugatti
S, Rund M, Metra M, McMurray JJ,
Teerlink JR, Cotter-Davison G.
Neurohumoral activation in heart
failure: results from VERITAS.
Cardiology 2011; 118: 96–105.
29. Nieminen MS, Brutsaert D, Dickstein K,
Drexler H, Follath F, Harjola V-K, Hochadel
M, Komajda M, Lassus J, Lopez-Sendon JL,
Ponikowski P, Tavazzi L, on behalf of the
EuroHeart Survey Investigators. EURO
Heart Survey II (EHFS II): a survey on
hospitalized acute heart failure patients:
description of population. Eur Heart J
2007; 27: 2725–2736.
30. Lund LH, Benson L, Dahlström U, Edner
M, Friberg L. Association between use of
β-blockers and outcomes in patients with
heart failure and preserved ejection
fraction. JAMA 2014; 312: 2008–2018.
204 K. Sotiropoulos et al.
ESC Heart Failure 2016; 3: 198–204
DOI: 10.1002/ehf2.12091
